Xintela AB: BioStock: Xintela highlights the unique properties of XSTEM
Biopharma company Xintela develops stem cell products with therapeutic properties aiming to treat diseases that currently lack effective treatment options. The company's stem cells stand out from others through a selection step in the production process that provides quality-assured, homogenous and pure stem cell preparations. BioStock talked to Lucienne Vonk, Director Musculoskeletal Diseases at Xintela, about the benefits of the company's stem cell products.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se